NO20021567L - Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger - Google Patents

Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger

Info

Publication number: NO20021567L
Authority: NO; Norway
Prior art keywords: acid; polypeptide; amino acid; arginine; variants
Prior art date: 1999-10-04

Application number

NO20021567A

Other languages

English (en)

Norwegian (no)

Other versions

NO20021567D0 (no

Inventor

Bao-Lu Chen

Maninder Hora

Original Assignee

Chiron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-04

Filing date

2002-04-03

Publication date

2002-05-22

2002-04-03 Application filed by Chiron Corp filed Critical Chiron Corp

2002-04-03 Publication of NO20021567D0 publication Critical patent/NO20021567D0/no

2002-05-22 Publication of NO20021567L publication Critical patent/NO20021567L/no

Links

239000007788 liquid Substances 0.000 title abstract 7
239000008194 pharmaceutical composition Substances 0.000 title abstract 7
229920001184 polypeptide Polymers 0.000 title abstract 7
102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
150000003839 salts Chemical group 0.000 abstract 8
235000001014 amino acid Nutrition 0.000 abstract 7
150000001413 amino acids Chemical class 0.000 abstract 7
239000004475 Arginine Substances 0.000 abstract 6
235000009697 arginine Nutrition 0.000 abstract 6
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 6
239000002253 acid Substances 0.000 abstract 5
239000002585 base Substances 0.000 abstract 5
102100030951 Tissue factor pathway inhibitor Human genes 0.000 abstract 4
230000015572 biosynthetic process Effects 0.000 abstract 4
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 abstract 4
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 3
239000004472 Lysine Substances 0.000 abstract 3
150000007513 acids Chemical class 0.000 abstract 3
235000003704 aspartic acid Nutrition 0.000 abstract 3
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
239000012458 free base Substances 0.000 abstract 3
235000013922 glutamic acid Nutrition 0.000 abstract 3
239000004220 glutamic acid Substances 0.000 abstract 3
235000018977 lysine Nutrition 0.000 abstract 3
239000000203 mixture Substances 0.000 abstract 3
102000000588 Interleukin-2 Human genes 0.000 abstract 2
108010002350 Interleukin-2 Proteins 0.000 abstract 2
239000006172 buffering agent Substances 0.000 abstract 2
239000012669 liquid formulation Substances 0.000 abstract 2
239000001384 succinic acid Substances 0.000 abstract 2
239000013543 active substance Substances 0.000 abstract 1
239000000872 buffer Substances 0.000 abstract 1
230000001747 exhibiting effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Virology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)

NO20021567A 1999-10-04 2002-04-03 Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger NO20021567L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15769699P	1999-10-04	1999-10-04
PCT/US2000/027156 WO2001024814A1 (en)	1999-10-04	2000-10-03	Stabilized liquid polypeptide-containing pharmaceutical compositions

Publications (2)

Publication Number	Publication Date
NO20021567D0 NO20021567D0 (no)	2002-04-03
NO20021567L true NO20021567L (no)	2002-05-22

Family

ID=22564882

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20021567A NO20021567L (no)	1999-10-04	2002-04-03	Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger
NO20044406A NO20044406L (no)	1999-10-04	2004-10-15	Stabilisert flytende farmasoytisk sammensetning samt fremgangsmate for a oke stabiliteten av IL-2

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20044406A NO20044406L (no)	1999-10-04	2004-10-15	Stabilisert flytende farmasoytisk sammensetning samt fremgangsmate for a oke stabiliteten av IL-2

Country Status (18)

Country	Link
US (4)	US6525102B1 (de)
EP (2)	EP1220682B1 (de)
JP (2)	JP2003510368A (de)
CN (2)	CN1245216C (de)
AT (2)	ATE345810T1 (de)
AU (2)	AU783306B2 (de)
BR (2)	BR0014486A (de)
CA (2)	CA2477857C (de)
CZ (2)	CZ20021186A3 (de)
DE (2)	DE60044213D1 (de)
ES (1)	ES2276698T3 (de)
HU (3)	HU227347B1 (de)
IL (3)	IL149008A0 (de)
NO (2)	NO20021567L (de)
NZ (2)	NZ535205A (de)
PL (2)	PL354987A1 (de)
PT (1)	PT1491208E (de)
WO (1)	WO2001024814A1 (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7006874B2 (en) *	1996-01-05	2006-02-28	Thermage, Inc.	Treatment apparatus with electromagnetic energy delivery device and non-volatile memory
JP2000247903A (ja) *	1999-03-01	2000-09-12	Chugai Pharmaceut Co Ltd	長期安定化製剤
CZ20021186A3 (cs) *	1999-10-04	2002-11-13	Chiron Corporation	Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
SK11142002A3 (sk) *	1999-12-30	2004-09-08	Chiron Corporation	Liečivo na podávanie interleukínu-2 a stabilizovaný lyofilizovaný alebo sprejovo sušený farmaceutický prostriedok s obsahom interleukínu-2
US6495534B2 (en)	2000-05-15	2002-12-17	Pharmacia & Upjohn Spa	Stabilized aqueous suspensions for parenteral use
EP1935431A3 (de)	2000-05-15	2008-08-13	Health Research, Inc.	Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
JP4147234B2 (ja) *	2004-09-27	2008-09-10	キヤノン株式会社	吐出用液体、吐出方法、カートリッジ及び吐出装置
AU2002213441B2 (en)	2000-10-12	2006-10-26	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
US8703126B2 (en)	2000-10-12	2014-04-22	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
CA2441192C (en) *	2001-03-23	2009-05-19	Ajinomoto Co., Inc.	The use of lysine for the prevention or treatment of stress-induced diseases
US6887462B2 (en) *	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
DE10149030A1 (de) *	2001-10-05	2003-04-10	Viscum Ag	Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
EA200400548A1 (ru)	2001-10-15	2005-06-30	Чирон Корпорейшн	Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
US7842668B1 (en)	2001-11-13	2010-11-30	Genentech, Inc.	Apo-2 ligand/trail formulations
EP1450847B1 (de)	2001-11-13	2010-09-29	Genentech, Inc.	Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
EP3210624A1 (de) *	2002-02-27	2017-08-30	Immunex Corporation	Stabilisierte tnfr-fc-zusammensetzung mit arginin
SI1478394T1 (sl)	2002-02-27	2008-12-31	Immunex Corp	STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
US6964778B1 (en) *	2002-09-06	2005-11-15	Health Research, Inc.	Temperature controlled content release from liposomes
US6991805B1 (en) *	2002-09-06	2006-01-31	Health Research, Inc.	Temperature sensitive control of liposome-cell adhesion
WO2004028557A1 (ja) *	2002-09-26	2004-04-08	Shionogi & Co., Ltd.	安定化されたタンパク組成物
CA2512680A1 (en) *	2003-01-08	2004-07-29	Chiron Corporation	Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
EP1803445A3 (de) *	2003-01-08	2007-11-21	Novartis Vaccines and Diagnostics, Inc.	Stabilisierte lyophilisierte Zubereitungen mit Gewebefaktor-Inhibitor (TFPI) oder Varianten des Gewebefaktor-Inhibitors
DE602004019761D1 (de) *	2003-01-08	2009-04-16	Novartis Vaccines & Diagnostic	Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
US20040208870A1 (en) *	2003-01-30	2004-10-21	Medimmune, Inc.	Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
US20040208869A1 (en) *	2003-01-30	2004-10-21	Medimmune, Inc.	Uses of anti-integrin alphanubeta3 antibody formulations
CN1767815A (zh) *	2003-03-31	2006-05-03	阿尔萨公司	非水单相载体和使用这类载体的制剂
MXPA05010555A (es)	2003-04-04	2006-03-09	Genentech Inc	Formulaciones de proteina y anticuerpo de alta concentracion.
US7291501B2 (en) *	2003-07-16	2007-11-06	Abbott Laboratories	Stable compositions for measuring human natriuretic peptides
US7445933B2 (en) *	2003-07-16	2008-11-04	Abbott Laboratories, Inc.	Stable calibrators or controls for measuring human natriuretic peptides
WO2005019265A1 (en) *	2003-08-13	2005-03-03	Chiron Corporation	Improved method of purifying tfpi and tfpi analogs
US7141544B2 (en)	2003-10-10	2006-11-28	Baxter International, Inc.	Stabilization of pharmaceutical protein formulations with small peptides
DE10348550A1 (de) *	2003-10-20	2005-06-16	Hexal Biotech Forschungsgmbh	Stabile wässrige G-CSF-haltige Zusammensetzungen
ATE447412T1 (de)	2003-11-04	2009-11-15	Novartis Vaccines & Diagnostic	Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
US20050136542A1 (en) *	2003-12-19	2005-06-23	Beckman Coulter, Inc.	Stabilized liquid reference solutions
WO2005063298A1 (en)	2003-12-23	2005-07-14	Pharmacia Corporation	Stable growth hormone liquid formulation
EP1712240B1 (de) *	2003-12-25	2015-09-09	Kyowa Hakko Kirin Co., Ltd.	Stabile medizinische zubereitung auf wasserbasis mit antikörper
EP1703916A2 (de) *	2004-01-13	2006-09-27	Vasogenix Pharmaceuticals, Inc.	Verfahren zur behandlung eines akuten myokardinfarkts mit einem mit dem calicitonin-gen in verbindung stehenden peptid sowie dieses enthaltende zusammensetzungen
JP2007517911A (ja) *	2004-01-13	2007-07-05	バソジェニックスファーマシューティカルズ，インコーポレイテッド	心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法
US7976847B2 (en) *	2004-01-13	2011-07-12	Vasogenix Pharmaceuticals, Inc.	Controlled release CGRP delivery composition for cardiovascular and renal indications
EP1729791A2 (de) *	2004-03-17	2006-12-13	Chiron Corporation	Behandlung schwerer, ambulant erworbener pneumonie mittels verabreichung des gewebefaktorinhibitors (tfpi)
RS57852B1 (sr) *	2004-04-02	2018-12-31	Swedish Orphan Biovitrum Ab Publ	Postupci za smanjenje agregacije il-1ra
JP4988562B2 (ja) *	2004-06-01	2012-08-01	アレストレーディングソシエテアノニム	安定化したインターフェロン液体製剤
US20060051347A1 (en)	2004-09-09	2006-03-09	Winter Charles M	Process for concentration of antibodies and therapeutic products thereof
DE102004059776A1 (de) *	2004-09-17	2006-04-06	Deutsches Zentrum für Luft- und Raumfahrt e.V.	Brennstoffzellensystem
JP4147235B2 (ja) *	2004-09-27	2008-09-10	キヤノン株式会社	吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置
BRPI0519430A2 (pt) *	2004-12-22	2009-02-10	Ambrx Inc	hormânio do crescimento humano modificado
CA2593112A1 (en) *	2005-01-21	2006-07-27	Alza Corporation	Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
CN100336557C (zh) *	2005-05-11	2007-09-12	北京双鹭药业股份有限公司	一种生长抑素的水溶液制剂、其制备方法及应用
CN100342909C (zh) *	2005-05-11	2007-10-17	北京双鹭药业股份有限公司	一种胸腺素α1的水溶液制剂、其制备方法及应用
CN100337684C (zh) *	2005-05-11	2007-09-19	北京双鹭药业股份有限公司	一种胸腺五肽的水溶液制剂、其制备方法及应用
US7964200B2 (en)	2005-05-18	2011-06-21	Children's Hospital & Research Center At Oakland	Methods and compositions for immunizing against Chlamydia infection
KR100769709B1 (ko) *	2005-05-31	2007-10-23	주식회사 대웅	인성장호르몬을 함유하는 안정한 액상 제제
BRPI0611901A2 (pt)	2005-06-14	2012-08-28	Amgen, Inc	composição, liofilizado, kit, e, processo para preparar uma composição
US20070027105A1 (en)	2005-07-26	2007-02-01	Alza Corporation	Peroxide removal from drug delivery vehicle
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
US20070191271A1 (en) *	2006-02-10	2007-08-16	Dow Pharmaceutical Sciences	Method for stabilizing polypeptides lacking methionine
WO2007103425A2 (en) *	2006-03-06	2007-09-13	Novartis Ag	Kits and methods for preparing pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi)
TW200806317A (en) *	2006-03-20	2008-02-01	Wyeth Corp	Methods for reducing protein aggregation
AR060487A1 (es)	2006-04-21	2008-06-18	Xoma Technology Ltd	Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
BRPI0621841B8 (pt) *	2006-07-06	2021-05-25	Daewoong Co Ltd	formulação líquida
CN105363022A (zh) *	2006-07-06	2016-03-02	株式会社大熊	稳定的人生长激素液体制剂
US7923425B2 (en) *	2006-08-21	2011-04-12	Henkel Ag & Co. Kgaa	Low-foaming, acidic low-temperature cleaner and process for cleaning surfaces
US7767206B2 (en)	2006-10-02	2010-08-03	Amgen Inc.	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2170268A2 (de) *	2007-06-25	2010-04-07	Amgen, Inc.	Zusammensetzungen von spezifischen bindungsmitteln für den hepatozyten-wachstumsfaktor
EP2173163A4 (de) *	2007-07-06	2010-12-08	Glaxosmithkline Llc	Antikörperformulierungen
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
PE20091174A1 (es)	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
MY152979A (en)	2008-01-09	2014-12-15	Sanofi Aventis Deutschland	Novel insulin derivatives having an extremely delayed time-action profile
NZ588603A (en)	2008-03-26	2012-03-30	Oramed Ltd	Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
MX2011005051A (es) *	2008-11-17	2011-06-01	Genentech Inc	Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas.
AU2010221156A1 (en) *	2009-03-06	2011-09-22	Genentech, Inc.	Antibody formulation
CN102596175A (zh)	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
EP2458990B1 (de) *	2009-07-28	2016-03-30	Merck Sharp & Dohme Corp.	Verfahren zur herstellung hochkonzentrierter lyophilisierter pharmazeutischer formulierungen
NZ713967A (en)	2009-07-28	2017-01-27	Shire Human Genetic Therapies	Compositions and methods for treating gaucher disease
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
EP2501367B1 (de) *	2009-11-17	2015-01-21	Ipsen Pharma S.A.S.	Formulierung für HGH- und RHIGF-1-Kombination
PH12012501364A1 (en)	2010-01-15	2012-10-22	Amgen K A Inc	Antibody formulation and therapeutic regimens
EP3409289B1 (de)	2010-02-26	2020-09-30	Novo Nordisk A/S	Stabile, antikörperhaltige zusammensetzungen
PT3345615T (pt)	2010-03-01	2020-01-17	Bayer Healthcare Llc	Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
RU2012153786A (ru) *	2010-05-28	2014-07-10	Ново Нордиск А/С	Стабильные многодозовые композиции, содержащие антитело и консервант
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
RU2593715C2 (ru)	2010-09-15	2016-08-10	Рэндэлл Дж. МРСНИ	Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина
US11246915B2 (en)	2010-09-15	2022-02-15	Applied Molecular Transport Inc.	Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2726495B1 (de) *	2011-06-28	2019-03-06	Leukocare Ag	Verfahren zum verhindern der entfaltung eines (poly)peptids und/oder induzieren der (neu)-faltung eines (poly)peptids
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN108771655A (zh)	2011-10-28	2018-11-09	诚信生物公司	含有氨基酸的蛋白质制剂
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
US8613919B1 (en)	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations
JP6171331B2 (ja) *	2012-12-25	2017-08-02	東ソー株式会社	Ｆｃ結合性タンパク質の精製方法および定量方法
WO2014106846A2 (en) *	2013-01-03	2014-07-10	Oramed Ltd.	Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
AR095398A1 (es)	2013-03-13	2015-10-14	Genentech Inc	Formulaciones con oxidación reducida
AR095399A1 (es)	2013-03-13	2015-10-14	Genentech Inc	Formulaciones con oxidación reducida, método
RU2707550C2 (ru) *	2013-03-13	2019-11-27	Дженентек, Инк.	Составы со сниженным окислением
JP2016513478A (ja)	2013-03-15	2016-05-16	ジェネンテック，インコーポレイテッド	細胞培養培地及び抗体を産生する方法
IL312865B2 (en)	2013-09-11	2025-06-01	Eagle Biologics Inc	Liquid protein formulations containing viscosity-lowering agents
JP2014062100A (ja) *	2013-11-05	2014-04-10	Glaxosmithkline Llc	抗体処方
BR112016015851A2 (pt)	2014-01-09	2017-08-08	Sanofi Sa	Formulações farmacêuticas estabilizadas de insulina aspart
MX2016008979A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
MX2016008978A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
US10260111B1 (en)	2014-01-20	2019-04-16	Brett Eric Etchebarne	Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
CN106470707A (zh)	2014-05-07	2017-03-01	应用分子运输有限责任公司	用于口服递送生物活性货物的cholix毒素衍生的融合分子
US10478498B2 (en)	2014-06-20	2019-11-19	Reform Biologics, Llc	Excipient compounds for biopolymer formulations
US11357857B2 (en)	2014-06-20	2022-06-14	Comera Life Sciences, Inc.	Excipient compounds for protein processing
WO2015196091A1 (en)	2014-06-20	2015-12-23	Reform Biologics, Llc	Viscosity-reducing excipient compounds for protein formulations
AU2015325055B2 (en)	2014-10-01	2021-02-25	Eagle Biologics, Inc.	Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
EP3229828B1 (de)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
AR103173A1 (es) *	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6247241B2 (ja) *	2015-02-27	2017-12-13	ノバルティスアーゲー	抗体処方
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
EP3287139B1 (de) *	2015-04-21	2021-08-11	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Nervenwachstumsfaktorzusammensetzung und injektionspulver
CN115400220A (zh)	2015-12-30	2022-11-29	豪夫迈·罗氏有限公司	减少聚山梨酯降解的制剂
WO2018038301A1 (en) *	2016-08-26	2018-03-01	Hugel Inc.	Stabilized liquid formulation of botulinum toxin and preparation method thereof
PT3528787T (pt)	2016-10-21	2026-03-11	Amgen Inc	Formulações farmacêuticas e métodos para produzir as mesmas
EP3596108A4 (de)	2017-03-15	2020-12-23	Pandion Operations, Inc.	Gezielte immuntoleranz
US10676516B2 (en)	2017-05-24	2020-06-09	Pandion Therapeutics, Inc.	Targeted immunotolerance
CN111182887A (zh) *	2017-06-14	2020-05-19	株式会社生物解决方案有限公司	用于改善皮肤皱纹或抗炎活性的包括物质p的化妆品组合物
IL272167B2 (en) *	2017-08-08	2024-02-01	Csl Behring Ag	Hemopexin formulations
USRE50550E1 (en)	2017-12-06	2025-08-26	Pandion Operations, Inc.	IL-2 muteins and uses thereof
US10174092B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
WO2019173787A1 (en)	2018-03-08	2019-09-12	Applied Molecular Transport Inc.	Toxin-derived delivery constructs for oral delivery
CN121513216A (zh)	2018-03-08	2026-02-13	应用分子转运公司	用于经口递送的毒素衍生的递送构建体
WO2019241534A1 (en) *	2018-06-13	2019-12-19	Akron Biotechnology, LLC.	Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions
BR112021023345A2 (pt)	2019-05-20	2022-02-01	Pandion Operations Inc	Imunotolerância com alvo em madcam
MX2022001975A (es)	2019-08-16	2022-03-11	Applied Molecular Transport Inc	Composiciones, formulaciones y produccion y purificacion de interleucinas.
BR112022013730A2 (pt) *	2020-01-13	2022-10-11	Aptevo Res & Development Llc	Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
CN115666621A (zh)	2020-01-13	2023-01-31	度勒科特公司	具有减少的杂质的持续释放药物递送系统及相关方法
EP4107187A4 (de)	2020-02-21	2024-07-03	Pandion Operations, Inc.	Gewebegezielte immuntoleranz mit einem cd39-effektor
CN118271419A (zh) *	2020-03-31	2024-07-02	韩美药品株式会社	新型免疫刺激il-2类似物
CA3203561A1 (en)	2021-01-12	2022-07-21	Adrian Neil Verity	Sustained release drug delivery systems and related methods
CN117120070B (zh) *	2021-03-11	2024-11-15	89生物公司	包含突变型fgf-21肽peg化缀合物的液体制剂
CA3211539A1 (en) *	2021-03-11	2022-09-15	Boris Schwartsburd	Liquid formulations comprising mutant fgf-21 peptide pegylated conjugates
KR20250093372A (ko)	2022-10-26	2025-06-24	니혼 메디피직스 가부시키가이샤	방사성 의약 조성물
AU2024231427A1 (en) *	2023-03-09	2025-09-04	Merck Sharp & Dohme Llc	Formulations comprising actriia polypeptide variants
CN119405595A (zh) *	2024-03-14	2025-02-11	程度胜	含重组人白细胞介素-2的药物组合物、药物制剂及其制备方法
CN118593451B (zh) *	2024-08-08	2024-10-15	卡瑞济(北京)生命科技有限公司	一种包含l-精氨酸的抗肿瘤药物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4966843A (en)	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
EP0158487B1 (de)	1984-04-09	1991-08-28	Takeda Chemical Industries, Ltd.	Stabile Interleukin-2-Zusammensetzung
JPS60215631A (ja) *	1984-04-09	1985-10-29	Takeda Chem Ind Ltd	インタ−ロイキン−２組成物
US4650674A (en) *	1984-07-05	1987-03-17	Genentech, Inc.	Synergistic cytotoxic composition
US5034225A (en) *	1985-12-17	1991-07-23	Genentech Inc.	Stabilized human tissue plasminogen activator compositions
JPH0645551B2 (ja) *	1986-01-07	1994-06-15	塩野義製薬株式会社	インタ−ロイキン−２組成物
US4894226A (en)	1986-11-14	1990-01-16	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4931543A (en)	1987-05-11	1990-06-05	Cetus Corporation	Process for recovering microbially produced interleukin-2
EP0303746B2 (de)	1987-08-21	1998-12-02	Mallinckrodt Group Inc.	Stabilisierung von Wachstumshormonen
US4883661A (en)	1987-10-09	1989-11-28	Daly John M	Use of arginine as an lymphokine synergist
US5078997A (en) *	1988-07-13	1992-01-07	Cetus Corporation	Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5272135A (en)	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
DE4111393A1 (de) *	1991-04-09	1992-10-15	Behringwerke Ag	Stabilisierte faktor viii-praeparationen
FR2684878B1 (fr)	1991-12-12	1994-02-11	Roussel Uclaf	Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
IL107887A (en) *	1992-12-08	2003-07-06	Ambi Inc	Stabilized lanthionine containing bacteriocin compositions
US5358708A (en)	1993-01-29	1994-10-25	Schering Corporation	Stabilization of protein formulations
US5580856A (en) *	1994-07-15	1996-12-03	Prestrelski; Steven J.	Formulation of a reconstituted protein, and method and kit for the production thereof
JP2000510813A (ja)	1995-02-06	2000-08-22	ジェネテイックス・インスティテュート・インコーポレイテッド	Ｉｌ−１２用処方
CA2223745C (en)	1995-06-07	2004-03-16	Chiron Corporation	Method of solubilizing, purifying, and refolding protein
US5888968A (en) *	1995-06-07	1999-03-30	Chiron Corporation	TFPI formulation
ES2434840T3 (es) *	1995-07-27	2013-12-17	Genentech, Inc.	Formulación de proteína liofilizada isotónica estable
AU4344697A (en) *	1996-10-04	1998-04-24	Amgen, Inc.	Pharmaceutical compositions containing an mpl ligand
JP2001504709A (ja) *	1997-01-31	2001-04-10	ヒューマンジノームサイエンシーズ，インコーポレイテッド	組織因子経路インヒビター３
ATE367828T1 (de)	1998-04-03	2007-08-15	Novartis Vaccines & Diagnostic	Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
CZ20021186A3 (cs) *	1999-10-04	2002-11-13	Chiron Corporation	Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
JP2004505016A (ja) *	2000-05-10	2004-02-19	ノボ　ノルディスク　アクティーゼルスカブ	第ＶＩＩａ因子及び第ＸＩＩＩ因子を含んで成る医薬組成物
AU2002213441B2 (en) *	2000-10-12	2006-10-26	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
PL364178A1 (en) *	2001-01-26	2004-12-13	Schering Corporation	Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions

2000
- 2000-10-03 CZ CZ20021186A patent/CZ20021186A3/cs unknown
- 2000-10-03 JP JP2001527813A patent/JP2003510368A/ja active Pending
- 2000-10-03 AT AT00968584T patent/ATE345810T1/de not_active IP Right Cessation
- 2000-10-03 HU HU0401975A patent/HU227347B1/hu unknown
- 2000-10-03 CN CNB008163286A patent/CN1245216C/zh not_active Expired - Fee Related
- 2000-10-03 WO PCT/US2000/027156 patent/WO2001024814A1/en not_active Ceased
- 2000-10-03 HU HU0203133A patent/HUP0203133A3/hu unknown
- 2000-10-03 PL PL00354987A patent/PL354987A1/xx not_active Application Discontinuation
- 2000-10-03 EP EP00968584A patent/EP1220682B1/de not_active Expired - Lifetime
- 2000-10-03 DE DE60044213T patent/DE60044213D1/de not_active Expired - Lifetime
- 2000-10-03 BR BR0014486-0A patent/BR0014486A/pt not_active Application Discontinuation
- 2000-10-03 EP EP04021066A patent/EP1491208B1/de not_active Expired - Lifetime
- 2000-10-03 AT AT04021066T patent/ATE464062T1/de not_active IP Right Cessation
- 2000-10-03 BR BRPI0017437A patent/BRPI0017437B8/pt not_active IP Right Cessation
- 2000-10-03 CZ CZ2004-1041A patent/CZ305123B6/cs not_active IP Right Cessation
- 2000-10-03 DE DE60031999T patent/DE60031999T2/de not_active Expired - Lifetime
- 2000-10-03 CA CA2477857A patent/CA2477857C/en not_active Expired - Lifetime
- 2000-10-03 IL IL14900800A patent/IL149008A0/xx unknown
- 2000-10-03 NZ NZ535205A patent/NZ535205A/en not_active IP Right Cessation
- 2000-10-03 ES ES00968584T patent/ES2276698T3/es not_active Expired - Lifetime
- 2000-10-03 NZ NZ529856A patent/NZ529856A/en unknown
- 2000-10-03 CN CNB2004100858470A patent/CN100389821C/zh not_active Expired - Lifetime
- 2000-10-03 US US09/677,643 patent/US6525102B1/en not_active Expired - Fee Related
- 2000-10-03 AU AU78475/00A patent/AU783306B2/en not_active Ceased
- 2000-10-03 PT PT04021066T patent/PT1491208E/pt unknown
- 2000-10-03 HU HU0800692A patent/HU0800692D0/hu unknown
- 2000-10-03 PL PL370852A patent/PL211886B1/pl not_active IP Right Cessation
- 2000-10-03 CA CA002386228A patent/CA2386228A1/en not_active Abandoned
2002
- 2002-04-03 NO NO20021567A patent/NO20021567L/no not_active Application Discontinuation
- 2002-04-04 IL IL149008A patent/IL149008A/en active IP Right Grant
- 2002-11-18 US US10/299,039 patent/US7030086B2/en not_active Expired - Fee Related
2004
- 2004-10-15 NO NO20044406A patent/NO20044406L/no not_active Application Discontinuation
- 2004-10-29 JP JP2004317319A patent/JP2005068158A/ja active Pending
2005
- 2005-12-05 US US11/293,322 patent/US7807142B2/en not_active Expired - Fee Related
- 2005-12-05 US US11/293,379 patent/US20060093598A1/en not_active Abandoned
2006
- 2006-01-13 AU AU2006200141A patent/AU2006200141B2/en not_active Ceased
2007
- 2007-12-18 IL IL188230A patent/IL188230A0/en unknown

Also Published As

Publication number	Publication date
CA2386228A1 (en)	2001-04-12
IL188230A0 (en)	2008-03-20
US6525102B1 (en)	2003-02-25
PL354987A1 (en)	2004-03-22
CN1402640A (zh)	2003-03-12
AU2006200141B2 (en)	2009-07-02
DE60031999D1 (de)	2007-01-04
NZ529856A (en)	2005-09-30
CN1636592A (zh)	2005-07-13
EP1220682A1 (de)	2002-07-10
HU0401975D0 (en)	2004-11-29
US20060093576A1 (en)	2006-05-04
CA2477857C (en)	2012-04-10
EP1491208B1 (de)	2010-04-14
BR0014486A (pt)	2002-09-17
ATE345810T1 (de)	2006-12-15
US7030086B2 (en)	2006-04-18
DE60031999T2 (de)	2007-06-06
HUP0203133A3 (en)	2005-07-28
WO2001024814A1 (en)	2001-04-12
CA2477857A1 (en)	2001-04-12
EP1220682B1 (de)	2006-11-22
HU0800692D0 (en)	2009-01-28
CZ20021186A3 (cs)	2002-11-13
BR0017437A (pt)	2002-09-17
JP2003510368A (ja)	2003-03-18
CN1245216C (zh)	2006-03-15
CZ305123B6 (cs)	2015-05-13
AU7847500A (en)	2001-05-10
NZ535205A (en)	2006-01-27
HUP0401975A3 (en)	2010-01-28
EP1491208A1 (de)	2004-12-29
IL149008A (en)	2009-11-18
NO20021567D0 (no)	2002-04-03
US7807142B2 (en)	2010-10-05
AU783306B2 (en)	2005-10-13
ES2276698T3 (es)	2007-07-01
DE60044213D1 (de)	2010-05-27
PT1491208E (pt)	2010-05-12
CN100389821C (zh)	2008-05-28
HU227347B1 (en)	2011-04-28
IL149008A0 (en)	2002-11-10
BRPI0017437B1 (pt)	2016-06-07
JP2005068158A (ja)	2005-03-17
NO20044406L (no)	2002-05-22
HUP0203133A2 (hu)	2002-12-28
US20030180253A1 (en)	2003-09-25
PL211886B1 (pl)	2012-07-31
US20060093598A1 (en)	2006-05-04
AU2006200141A1 (en)	2006-02-09
BRPI0017437B8 (pt)	2021-05-25
ATE464062T1 (de)	2010-04-15

Legal Events

Date	Code	Title	Description
2010-05-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20021567L (no)	2002-05-22	Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger
EP1401473A4 (de)	2004-07-28	Transporter mit beabstandeten arginin-teilchen
TR200200252T2 (tr)	2002-05-21	Şimerik polipeptidler, bunların üretimi için yöntem ve kullanımı
MXPA03011041A (es)	2004-03-19	Composiciones farmaceuticas que contienen orlistat y acidos grasos y/o sales de los mismos.
CA2402191A1 (en)	2001-10-04	Use of insulin for the treatment of cartilagenous disorders
EE04911B1 (et)	2007-10-15	Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
EA200200938A1 (ru)	2003-02-27	Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
IL112222A (en)	1999-12-31	Pharmaceutical compositions containing n-substituted azaheterocyclic carboxylic acids and esters thereof certain such compounds and their preparation
ATE404176T1 (de)	2008-08-15	Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
NO20020176L (no)	2002-01-14	Sykliske peptidderivater som inhibitorer for intergrin <alfa>v<beta>6
CA2480226A1 (en)	2003-10-02	Stable pharmaceutical composition containing factor viii
DK1588707T3 (da)	2009-03-09	Stabilt fast medicinsk præparat til oral administration af ramosetron
EA200401298A1 (ru)	2005-02-24	Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение
BR0211060A (pt)	2004-07-20	Formulação lìquida compreendendo cetuximab e um éster de ácido graxo de polioxietileno sorbitano
FR2846883B1 (fr)	2004-12-24	Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide
WO2003026582A3 (en)	2003-10-16	Method of preparing phenoxy alkanoic, alkenoic, and alkynoic acids and salts thereof via a dicarboxylate intermediate
BR9908479A (pt)	2000-12-05	Composições farmacêuticas que contêm o inibidor de fosfolipase [[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil_-1h-indol- 4-il]óxil] acetato de sódio
GEP20115206B (en)	2011-04-26	Novel piperidine carboxylic acid amide derivatives
DE69918098D1 (de)	2004-07-22	Neue suesstoffzusammensetzungen
ATE335409T1 (de)	2006-09-15	Suesstoffzusammensetzung
DE69208171D1 (de)	1996-03-21	Gallensäuren enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
KR900014429A (ko)	1990-10-23	폴리펩티드 유도체 및 칼슘 대사 향진제
AU5270696A (en)	1996-10-23	Novel heterocyclic compounds
JPH04270227A (ja)	1992-09-25	ヒト組織プラスミノーゲン活性化因子含有組成物
IT1307866B1 (it)	2001-11-19	Composizioni farmaceutiche contenenti inibitori dell'ormone dellacrescita o loro frammenti biologicamente attivi per il trattamento